Travere Therapeutics 관리
관리 기준 확인 2/4
Travere Therapeutics CEO는 Eric Dube, Jan2019 에 임명되었습니다 의 임기는 5.83 년입니다. 총 연간 보상은 $ 7.57M, 10.5% 로 구성됩니다. 10.5% 급여 및 89.5% 보너스(회사 주식 및 옵션 포함). 는 $ 2.10M 가치에 해당하는 회사 주식의 0.14% 직접 소유합니다. 2.10M. 경영진과 이사회의 평균 재임 기간은 각각 4.1 년과 7.6 년입니다.
주요 정보
Eric Dube
최고 경영자
US$7.6m
총 보상
| CEO 급여 비율 | 10.5% |
| CEO 임기 | 5.8yrs |
| CEO 소유권 | 0.1% |
| 경영진 평균 재임 기간 | 4.1yrs |
| 이사회 평균 재임 기간 | 7.6yrs |
최근 관리 업데이트
Recent updates
Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Shares Bounce 27% But Its Business Still Trails The Industry
Oct 31
Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?
Oct 07Travere Therapeutics Faces Challenges But Holds Promise With Filspari Beyond IgAN
Sep 30Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Boosted 29% But Its Business Prospects Need A Lift Too
Sep 10Travere Therapeutics: Judgement Day Is Nigh For Sparsentan
Aug 30Shareholders May Be More Conservative With Travere Therapeutics, Inc.'s (NASDAQ:TVTX) CEO Compensation For Now
May 02Lacklustre Performance Is Driving Travere Therapeutics, Inc.'s (NASDAQ:TVTX) 29% Price Drop
Apr 20Travere Therapeutics: Restructuring Away From Disaster
Jan 30Travere Therapeutics (NASDAQ:TVTX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Jan 22Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Boosted 48% But Its Business Prospects Need A Lift Too
Dec 18New Forecasts: Here's What Analysts Think The Future Holds For Travere Therapeutics, Inc. (NASDAQ:TVTX)
Aug 08Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?
Jun 09It's Down 27% But Travere Therapeutics, Inc. (NASDAQ:TVTX) Could Be Riskier Than It Looks
May 05Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?
Feb 16Travere Therapeutics' FDA target action date for nephropathy treatment extended
Oct 13Is Travere Therapeutics (NASDAQ:TVTX) Weighed On By Its Debt Load?
Oct 06Travere Therapeutics: Changes In The Risk-Reward Assessment
Sep 29Travere, CSL kidney disease drug sparsentan gets review in EU
Aug 22Travere Therapeutics GAAP EPS of -$1.05 misses by $0.14, revenue of $54.2M beats by $4.7M
Aug 04Travere Theraspeutics a new buy at Canaccord as a 'rare disease powerhouse'
Jul 14Is Travere Therapeutics (NASDAQ:TVTX) Weighed On By Its Debt Load?
Jun 19CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$349m |
| Jun 30 2024 | n/a | n/a | -US$383m |
| Mar 31 2024 | n/a | n/a | -US$416m |
| Dec 31 2023 | US$8m | US$796k | -US$376m |
| Sep 30 2023 | n/a | n/a | -US$373m |
| Jun 30 2023 | n/a | n/a | -US$368m |
| Mar 31 2023 | n/a | n/a | -US$352m |
| Dec 31 2022 | US$6m | US$747k | -US$331m |
| Sep 30 2022 | n/a | n/a | -US$297m |
| Jun 30 2022 | n/a | n/a | -US$249m |
| Mar 31 2022 | n/a | n/a | -US$202m |
| Dec 31 2021 | US$6m | US$708k | -US$217m |
| Sep 30 2021 | n/a | n/a | -US$250m |
| Jun 30 2021 | n/a | n/a | -US$237m |
| Mar 31 2021 | n/a | n/a | -US$224m |
| Dec 31 2020 | US$5m | US$661k | -US$169m |
| Sep 30 2020 | n/a | n/a | -US$78m |
| Jun 30 2020 | n/a | n/a | -US$92m |
| Mar 31 2020 | n/a | n/a | -US$105m |
| Dec 31 2019 | US$10m | US$618k | -US$146m |
보상 대 시장: Eric 의 총 보상 ($USD 7.57M )은 US 시장( $USD 5.38M ).
보상과 수익: 회사가 수익성이 없는 동안 Eric 의 보상이 증가했습니다.
CEO
Eric Dube (51 yo)
5.8yrs
테뉴어
US$7,574,959
보상
Dr. Eric M. Dube, Ph D., serves as an Independent Director at Reneo Pharmaceuticals, Inc. since March 2021. Dr. Dube serves as President and Chief Executive Officer at Travere Therapeutics, Inc. (formerly...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| President | 5.8yrs | US$7.57m | 0.14% $ 2.1m | |
| Chief Financial Officer | 2.3yrs | US$1.97m | 0.086% $ 1.3m | |
| Senior VP | 7.8yrs | US$2.02m | 0.090% $ 1.4m | |
| Senior VP and Head of Research & Development | 7.8yrs | US$2.05m | 0.041% $ 619.0k | |
| Chief Commercial Officer | 5.1yrs | US$2.00m | 0.068% $ 1.0m | |
| SVP, Corporate Controller & Chief Accounting Officer | 3.2yrs | 데이터 없음 | 0.060% $ 904.6k | |
| Vice President of Corporate Communications & Investor Relations | no data | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Human Resources | no data | 데이터 없음 | 데이터 없음 | |
| Chief Business Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| Chief Medical Officer | 2.8yrs | US$2.87m | 0.071% $ 1.1m | |
| Senior Vice President of Public Affairs | no data | 데이터 없음 | 데이터 없음 |
4.1yrs
평균 재임 기간
52yo
평균 연령
경험이 풍부한 관리: TVTX 의 관리팀은 경험 ( 4.1 년 평균 재직 기간)으로 간주됩니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| President | 5.8yrs | US$7.57m | 0.14% $ 2.1m | |
| Independent Director | 7.7yrs | US$372.98k | 0.033% $ 502.2k | |
| Independent Chairman of the Board | 10.1yrs | US$392.98k | 0.059% $ 886.9k | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Independent Director | 4.6yrs | US$372.36k | 0.026% $ 386.9k | |
| Independent Director | 8.4yrs | US$376.73k | 0.036% $ 539.1k | |
| Independent Director | 3.2yrs | US$365.48k | 0.022% $ 334.8k | |
| Independent Director | 9.7yrs | US$385.48k | 0.056% $ 852.1k | |
| Independent Director | 7.6yrs | US$367.98k | 0.033% $ 502.2k | |
| Independent Director | 10.1yrs | US$379.98k | 0.093% $ 1.4m | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Independent Director | 5.5yrs | US$369.86k | 0.027% $ 408.7k |
7.6yrs
평균 재임 기간
60yo
평균 연령
경험이 풍부한 이사회: TVTX 의 이사회는 경험(평균 재직 기간 7.6 년)으로 간주됩니다.